The Current Understanding of and Treatment Paradigm for Newly-Diagnosed <i>TP53</i>-Mutated Acute Myeloid Leukemia
About 10% of newly diagnosed and 20–30% of therapy-related acute myeloid leukemia (AML) harbors a <i>TP53</i> mutation (<i>mTP53</i>-AML). Unfortunately, this biological subset predicts one of the worst prognoses among patients with AML, specifically a median overall survival...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Hemato |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-6357/2/4/51 |